Douglas Johnson

Jan 23, 2025 | nature.com | Douglas Johnson

The human gut microbiome plays a vital role in aiding digestion, regulating host immunity, metabolism, protecting against pathogens and overall health1. In children, the development of the gut microbiome over the first two to three years of life is crucial, acting as a critical period that shapes lifelong health outcomes2. Despite its importance, our understanding of how the gut microbiome evolves in infancy and its implications for future health remains incomplete.

Mar 26, 2024 | nature.com | Pooja Middha |Michael Betti |Cosmin Bejan |Douglas Johnson |Linda Kachuri |Christine Lovly | +4 more

AbstractImmune checkpoint inhibitor-mediated colitis (IMC) is a common adverse event of treatment with immune checkpoint inhibitors (ICI). We hypothesize that genetic susceptibility to Crohn’s disease (CD) and ulcerative colitis (UC) predisposes to IMC.

Feb 26, 2024 | medicalxpress.com | Douglas Johnson

As the years add up, it's common to notice slight changes in our ability to remember and think. Older people who have more marked changes than their peers can be diagnosed with mild cognitive impairment (MCI). Currently, we can't easily predict which of these patients will develop Alzheimer's disease and which will not.

Aug 17, 2023 | nature.com | Ari Vander Walde |Katie Campbell |Philip O. Scumpia |Alexandra Ikeguchi |Bartosz Chmielowski |Kim Margolin | +3 more

AbstractIn this randomized phase 2 trial, blockade of cytotoxic T-lymphocyte protein 4 (CTLA-4) with continuation of programmed death protein 1 (PD-1) blockade in patients with metastatic melanoma who had received front-line anti-PD-1 or therapy against programmed cell death 1 ligand 1 and whose tumors progressed was tested in comparison with CTLA-4 blockade alone.

Apr 11, 2023 | nature.com | Douglas Johnson

Immune-checkpoint-inhibitor-associated myocarditis has a high fatality rate, warranting the development of more-effective treatment strategies. Herein, we discuss a recent report of a series of patients who were managed using a novel approach that involved personalized abatacept dosing, ruxolitinib and close respiratory monitoring, which was associated with low mortality. Refers to Salem, J. E. et al.